

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1


<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Origin BioMed Inc.	05/04/2011
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NeuroQuest Inc.
<b>Street Address:</b>	5162 Duke Street, Suite 520
<b>City:</b>	Halifax, Nova Scotia
<b>State/Country:</b>	CANADA
<b>Postal Code:</b>	B3J 1N7
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	12537095
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(405)607-8686
<b>Phone:</b>	405-607-8600
<b>Email:</b>	bnolte@dunlapcoddington.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Correspondent Name:</b>	DUNLAP CODDING, P.C.
<b>Address Line 1:</b>	PO BOX 16370
<b>Address Line 4:</b>	OKLAHOMA CITY, OKLAHOMA 73113
<b>ATTORNEY DOCKET NUMBER:</b>	6031.005
<b>NAME OF SUBMITTER:</b>	Douglas J. Sorocco
<b>Total Attachments: 1</b> source=6031005_ExecutedAssignment_OriginBioMedInc_to_NeuroQuestInc#page1.tif	

OP \$40.00 12537095

**CONFIRMATORY ASSIGNMENT**


We, **ORIGIN BIOMED INC.**, whose full post office address is **5162 Duke Street, Suite 520, Halifax, Nova Scotia B3J 1N7, Canada**, in consideration of the sum of Ten Dollars (\$10.00), the receipt and sufficiency of which are hereby acknowledged, have sold and assigned and do hereby sell and assign to **NeuroQuest Inc.**, whose full post office address is **5162 Duke Street, Suite 520, Halifax, Nova Scotia B3J 1N7, Canada**, all our right, title and interest in Canada and the United States of America, in and to our invention relating to "**Composition Comprising Terpene Compounds and Methods for Inhibiting Nerve Transmission**", as fully described and claimed in our Canadian Patent Application No. **2,676,139**, filed **February 6, 2008**, and in our United States Patent Application No. **12/537,095**, filed **February 6, 2008**, for patents for such invention, and to all our corresponding right, title and interest in and to any patent which may issue therefor; this sale and assignment having taken effect as of December 18, 2009.

SIGNED at



Signature of Witness

this 4th day of May, 2011.



**Mr. Robert Dingee, CEO**  
**ORIGIN BIOMED INC.**